Maureen introduces the concept of pharmacoequity and the IRA’s potential positive and negative impacts on it. She provides solutions for payers and pharmaceutical companies to improve health equity and promote pharmacoequity.
An overarching theme throughout the health care ecosystem—including behavioral health—is that within a landscape fraught with post-pandemic and economic transitional uncertainty, patients and their care partners expect health care stakeholders to simplify complexity, help manage risks, and solve their problems. A 2023 Bain survey, and an NEJM article, “Health Care 2030: The Coming Transformation,” are calling for the abandonment of traditional perspectives, and adoption of transformative mindsets and systems focused on providing solutions and offering personalized, preventive care for populations.
Three years into the pandemic, a recent Lancet editorial observed, “The acute months of the COVID-19 pandemic motivated an unprecedented response from governments, international organisations, pharmaceutical companies, and civil society.” As we transition to a different phase of this pandemic, the need for multistakeholder collaboration continues, to build resilience and prevent or mitigate future pandemics.
The Centers for Medicare & Medicaid Services (CMS) recognize that health care spending rises as a percent of gross domestic product (GDP) yearly while also underperforming on quality and equity. In this article we will review current and emerging initiatives including new and proposed SDOH quality measures and activities linked to plan and provider payments and incentives, discuss barriers to success, and propose win-win solutions for pharmaceutical companies to advance these initiatives.
Stay up to date on the changes to the 2022 QPP proposed quality measures and improvement activities with an overview from Maureen Hennessey, as well as suggested landscape analysis and customer partnership opportunities for pharmaceutical manufacturers in the quality and clinical improvement areas.
Telehealth vendors, health systems, and clinicians are seeing opportunities to further expand delivery of reimbursable telehealth services since CMS issued its (CY) 2021 Medicare Physician Fee Scale final rule on December 1, 2020. Precision’s Maureen Hennessey discussing the impact of these expanded opportunities, and how they set the stage for amping up the velocity for telehealth growth.
Maureen Hennessey from our Quality and Population Health Solutions team provides an overview of MACRA, Medicare’s evolution toward value-based clinical reimbursement. Maureen breaks down the separate tracks of participation for providers and highlights some guidelines for demonstrating value that manufacturers will need to demonstrate.
